Lyophilised Oxalobacter formigenes - OxThera AB

Drug Profile

Lyophilised Oxalobacter formigenes - OxThera AB

Alternative Names: IxOC 3; Lyophylised Oxalobacter formigenes; OC 3; OC5; Oxabact; Oxalobacter

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ixion Biotechnology
  • Developer OxThera
  • Class Bacteria; Probiotics
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria; Short bowel syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Primary hyperoxaluria
  • No development reported Short bowel syndrome

Most Recent Events

  • 09 Jan 2018 Phase-III clinical trials in Primary hyperoxaluria (In children, In adolescents, In adults, In the elderly) in Spain, Germany, Netherlands (PO) (NCT03116685) (EudraCT2017-000684-33)
  • 08 Nov 2017 oxThera has patent protection for Oxalobacter formigenes in Europe, Canada, China, Hong-Kong, India and Japan
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Short-bowel-syndrome in Sweden (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top